Top

Published in:

01-06-2012 | Management of Heart Failure (T Meyer, Section Editor)

Chemotherapy-Induced Cardiotoxicity

Authors: Amir Y. Shaikh, Jeffrey A. Shih

Published in: Current Heart Failure Reports | Issue 2/2012

Abstract

Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.

Geiger S, Lange V, Suhl P, et al. Anticancer therapy induced cardiotoxicity: review of the literature. Anti Canc Drug. 2010;21(6):578–90.CrossRef

•• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29;10:337. This is a thorough review of the literature. Due to the small trials, meta-analyses are essential with regards to this topic. PubMedCrossRef

Zuppinger C, Suter TM. Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J Cardiovasc Pharmacol. 2010;56(2):141–6.PubMedCrossRef

•• van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005006. This is an effective Cochrane review on preventing or reducing cardiotoxicity from anthracyclines.

Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in survivors of childhood cancer. NEJM. 2006;355(15):1572–82.PubMedCrossRef

• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231–47. This is an excellent review on the topic. PubMedCrossRef

Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.PubMed

Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105–13.PubMedCrossRef

Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.PubMedCrossRef

10.

Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.PubMedCrossRef

11.

Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6.PubMedCrossRef

12.

Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53(2):114–20.PubMedCrossRef

13.

Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31.PubMedCrossRef

14.

Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002;4(3):235–42.PubMedCrossRef

15.

Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31–6.PubMed

16.

Martin M, Pienkowski T, Mackey J, Breast Cancer International Research Group 001 Investigators, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–13.PubMedCrossRef

17.

Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9(4):320–8.PubMedCrossRef

18.

Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27(5B):3465–70.PubMed

19.

Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.PubMedCrossRef

20.

Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRef

21.

Palumbo A, Rajkumar SV, Dimopoulos MA, International Myeloma Working Group, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.PubMedCrossRef

22.

Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609–15.PubMedCrossRef

23.

Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Canc Inst. 2010;102(1):14–25.CrossRef

24.

Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461–70.PubMedCrossRef

25.

Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118(1):92–8.PubMedCrossRef

26.

Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994;33(6):645–9.PubMedCrossRef

27.

Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68(2):435–8.PubMedCrossRef

28.

Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992;19(2):394–401.PubMedCrossRef

29.

• Sawaya H, Sebag IA, Plana JC, et al. Early detection and predictor of cardiotoxicity in chemotherapy- treated patients. Am J Cardiol. 2011;107:1375–80. This is a recent article reviewing the risk factors, surveillance, and means of identifying cardiotoxicity. PubMedCrossRef

30.

Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517–22.PubMedCrossRef

31.

Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54.PubMedCrossRef

32.

Cardinale D, Salvatici M, Sandri MT. Review: role of biomarkers in cardioncology. Clin Chem Lab Med. 2011 Sep 6.

33.

Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.PubMedCrossRef

34.

Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14.PubMedCrossRef

35.

Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900–5.PubMedCrossRef

36.

Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risk analysis of 1097 breast cancer patients. J Natl Canc Inst. 2008;100:1058.CrossRef

37.

Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Investig New Drugs. 1985;3:123.

38.

Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005–24.PubMedCrossRef

39.

Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117–27.PubMed

40.

Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–32.PubMed

41.

Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996;14:3112–20.PubMed

42.

Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362–72.PubMed

43.

Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of highdose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998;16:86–92.PubMed

44.

Marty M, Espie M, Llombart A, Dexrazoxane Study G, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17:614–22.PubMedCrossRef

45.

• van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008:CD003917. This is a typical Cochrane review on cardioprotective strategies with anthracyclines.

46.

Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–62.PubMedCrossRef

47.

Waldner R, Laschan C, Lohninger A, et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 2006;132:121–8.PubMedCrossRef

48.

Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;10:53–5.PubMed

49.

Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492.PubMedCrossRef

50.

al-Shabanah O, Mansour M, el-Kashef H, et al. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int. 1998;45:419–27.PubMed

51.

Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71–8.PubMedCrossRef

52.

Vaynblat M, Shah HR, Bhaskaran D, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–6.PubMedCrossRef

53.

• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. This is a rare prospective study assessing treatment with standard heart failure medications. Unfortunately, there was no comparative placebo arm. PubMedCrossRef

54.

Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56:1644.PubMedCrossRef

55.

Fazio S, Calmieri EA, Ferravate B, et al. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998;21:777–9.PubMedCrossRef

56.

Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6:115–9.PubMed

57.

Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709.PubMedCrossRef

58.

Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:517–22.

59.

Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:201–19.CrossRef

60.

Musci M, Loebe M, Grauhan O, et al. Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents. Transplant Proc. 1997;29(1–2):578–9.PubMedCrossRef

61.

Dorent R, Pavie A, Nataf P, et al. Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy. Transplant Proc. 1995;27(2):1683.PubMed

62.

Christiansen S. Clinical management of doxorubicin-induced heart failure. J Cardiovasc Surg. 2011;52:13–7.

63.

Harris L, Batist G, Belt R, TLC D-99 Study Group, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94(1):25–36.PubMedCrossRef

64.

Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444–54.PubMed

Title: Chemotherapy-Induced Cardiotoxicity
Authors: Amir Y. Shaikh
Jeffrey A. Shih
Publication date: 01-06-2012
Publisher: Current Science Inc.
Published in: Current Heart Failure Reports / Issue 2/2012
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-012-0083-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

TNF Revisited: Osteoprotegerin and TNF-related Molecules in Heart Failure

Role of Physical Training in Heart Failure with Preserved Ejection Fraction

Prognostic Value of Combining Echocardiography and Natriuretic Peptide Levels in Patients with Heart Failure

Skeletal Muscle Abnormalities in Chronic Heart Failure

The Neurohormonal Network in the RAAS Can Bend Before Breaking

Role of Heart Rate as a Marker and Mediator of Poor Outcome for Patients with Heart Failure

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials